- Home
- VRNS vs TVTX Comparison
VRNS vs TVTX Comparison
Compare VRNS & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRNS | TVTX |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.1B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | VRNS | TVTX |
|---|---|---|
| Price | $32.44 | $34.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 15 |
| Target Price | ★ $60.68 | $37.21 |
| AVG Volume (30 Days) | ★ 1.8M | 1.7M |
| Earning Date | 10-28-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $608,677,000.00 | $435,826,000.00 |
| Revenue This Year | $14.75 | $108.68 |
| Revenue Next Year | $16.12 | $40.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 11.37 | ★ 114.22 |
| 52 Week Low | $30.34 | $12.91 |
| 52 Week High | $63.90 | $37.50 |
Technical Indicators
Market Signals| Indicator | VRNS | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 28.57 | 59.55 |
| Support Level | $30.34 | $34.18 |
| Resistance Level | $33.39 | $37.50 |
| Average True Range (ATR) | 1.06 | 1.77 |
| MACD | 0.81 | -0.31 |
| Stochastic Oscillator | 32.08 | 48.65 |
Price Performance
Historical ComparisonAbout VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.